<DOC>
	<DOCNO>NCT01852266</DOCNO>
	<brief_summary>Human respiratory syncytial virus ( RSV ) common cause respiratory illness infant child . This study evaluate safety immune response RSV vaccine healthy RSV-naïve child .</brief_summary>
	<brief_title>Evaluating Safety Immune Response Single Dose Respiratory Syncytial Virus ( RSV ) Vaccine RSV-Seronegative Infants Children</brief_title>
	<detailed_description>RSV common viral cause serious acute lower respiratory illness ( LRI ) infants child 5 year age around world . RSV illness range mild upper respiratory tract illness ( URI ) severe LRI , include bronchiolitis pneumonia . This study evaluate safety immunogenicity RSV vaccine healthy RSV-naïve child . At study entry , participant undergo medical history review , physical examination , blood collection , nasal wash . Participants randomly assign receive RSV vaccine placebo 2:1 ratio , administer nose drop . Subjects actively monitor 28 day follow administration vaccine placebo ; monitor include medical history review , clinical assessment , visit , nasal wash . On day study visit schedule , study researcher contact participant ' parent guardian medical follow-up . At study visit Day 56 , participant undergo medical history review , blood collection , nasal wash procedure . From November March follow subject 's study participation , parent guardian report respiratory and/or febrile illness weekly basis via telephone call study researcher . Participants may additional study visit may include blood collection and/or nasal wash procedure follow-up period . This protocol companion study P1114 ; study conduct Center Immunization Research ( CIR , Johns Hopkins , Baltimore ) , Laboratory Infectious Diseases ( NIAID , Bethesda ) . The protocols identical primary secondary objective ; immunization schedule ; evaluation assay schedule ; safety monitoring reporting . The protocol vary slightly site selection requirement , eligibility requirement site monitoring . These operational issue modify account IMPAACT sit ' operation infrastructure .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At least 6 month le 25 month age time enrollment Parents/guardians demonstrate understand study ( take comprehension assessment ) , sign informed consent , agree vaccine administration follow detailed explanation study Seronegative RSV antibody , define serum RSV neutralize antibody titer le 1:40 determine within 42 day prior enrollment Participant 's history review participant undergone physical examination indicate s/he good health In view site investigator , participant receive routine immunization appropriate age Participant expect available duration study Known suspect impairment immunological function , include maternal history positive HIV test Receipt immunosuppressive therapy include systemic corticosteroid within 30 day study entry . NOTE : Topical steroid , topical antibiotic , topical antifungal medication acceptable within 24 hour enrollment . May reassess symptom resolve . Bone marrow/solid organ transplant recipient Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previous immunization RSV vaccine previous receipt plan administration antiRSV antibody product Previous serious vaccineassociated AE anaphylactic reaction Known hypersensitivity vaccine component Lung heart disease , include wheeze event reactive airway disease . Participants clinically insignificant cardiac abnormality require treatment may enrol . Participants one episode wheeze receive bronchodilator therapy single episode illness first year life additional wheezing episode bronchodilator therapy least 12 month may also enrol . Member household include immunocompromised individual infant le 6 month age Attends day care infant less 6 month age , whose parent/guardian unable unwilling suspend daycare 14 day follow immunization . Children attend facility separate child age minimize opportunity transmission virus direct physical aerosol contact acceptable . Fever ( rectal temperature great equal 100.4°F [ 38°C ] ) , upper respiratory illness ( rhinorrhea , cough , pharyngitis ) nasal congestion ( significant enough interfere successful vaccination ) , otitis medium Has receive kill vaccine live attenuate rotavirus vaccine within last 2 week , live vaccine within last 4 week , gamma globulin ( antibody product ) within past 3 month schedule receive immunization 28 day enrollment Receipt another investigational vaccine investigational drug within 28 day receive investigational RSV vaccine Has receive antibiotic systemic nasal steroid therapy prescription medication acute illness within 3 day study entry . Permitted concomitant medication include nutritional supplement , medication gastroesophageal reflux , eye drop , topical medication , include ( limited ) topical steroid , topical antibiotic , topical antifungal agent . Has receive salicylate ( aspirin ) salicylatecontaining product within past month Infants bear less 37 week gestation le 1 year age</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>